/
ATYR
$0.57+$0.04 (+7.37%)prev close
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$51.7M
98M shares
52-week range
$0.40 – $7.29
2% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
1.56%
Moderate
Price (6 mo)
Loading chart…
Change$-1.25
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $422.0K | $10.5M | $0 | $10.4M | $353.0K | $235.0K | $190.0K |
| Cost of revenue | $746.0K | $14.0M | $17.3M | $1.3M | $1.7M | $0 | $0 | $1.6M |
| Gross profit | −$746.0K | −$13.6M | −$6.8M | −$1.3M | $8.7M | $353.0K | $235.0K | −$1.4M |
| Gross margin | — | -3228.9% | -65.4% | — | 83.7% | 100.0% | 100.0% | -717.4% |
| R&D | $20.4M | $14.0M | $17.3M | $23.3M | $42.8M | $42.3M | $54.4M | $60.2M |
| Operating income | −$32.8M | −$23.0M | −$15.9M | −$34.0M | −$46.4M | −$54.9M | −$67.9M | −$77.6M |
| EBITDA | −$32.1M | −$22.3M | −$14.6M | −$32.5M | −$43.6M | −$47.7M | −$62.5M | −$72.6M |
| Net income | −$34.5M | −$23.6M | −$16.2M | −$33.8M | −$45.3M | −$50.4M | −$64.0M | −$74.1M |
| Net margin | — | -5593.1% | -155.2% | — | -436.5% | -14274.5% | -27243.8% | -39009.5% |
| EPS (diluted) | -16.13 | -7.03 | -1.77 | -1.77 | -1.60 | -0.94 | -0.86 | -0.80 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $4M | $-0.57 | $-0.59–$-0.55 | 4 |
| 2027 | $9M | $-0.65 | $-0.73–$-0.56 | 6 |
| 2028 | $53M | $-0.60 | $-0.98–$-0.35 | 7 |
| 2029 | $200M | $-0.42 | $-0.42–$-0.42 | 2 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
aTyr Pharma, Inc. Common Stock
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
www.atyrpharma.com- Employees
- 58
- IPO / List date
- May 7, 2015
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds ATYR.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 40,522 | $31.6K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ATYR yet.
